Table 5.
Baseline (N = 106) | 12 weeks (N = 91) | Adjusted difference* | 95% CI | p | ICC | |
---|---|---|---|---|---|---|
BBS (0–56) [SD] | 6.18 | 2.38,9.97 | 0.003 | 0.08 | ||
Control | 40.6 [13.1]) | 37.6 [14.9] | ||||
Exergames | 42.0 [13.5]) | 44.6 [10.7] | ||||
ACE III (0–100) [SD] | − 0.83 | − 4.10,2.45 | 0.60 | < 0.001 | ||
Control | 73.5 [12.1] | 80.2 [12.9 | ||||
Exergames | 77.4 [15.6] | 81.4 (14.2) | ||||
7-item FES-I (7–28) [SD] | − 2.69 | − 4.52, − 0.85 | 0.007 | 0.12 | ||
Control | 11.6 [4.5] | 12.8 [4.8] | ||||
Exergames | 11.0 [4.2] | 9.8 [3.4] | ||||
VAS pain scale (0–100) [%] | − 12.07 | − 22.31, − 1.83 | 0.024 | < 0.001 | ||
Control | 24.3 [26.5] | 34.4 [30.5] | ||||
Exergames | 23.9 (25.9) | 21.9 [27.7] | ||||
VAS fatigue scale (%) | − 6.63 | − 20.58, 7.32 | 0.33 | 0.10 | ||
Control | 32.4 [26.6] | 39.2 [28.0] | ||||
Exergames | 37.5 [31.2] | 34.6 [31.3] | ||||
FRAT (0–5) [SD] | − 0.15 | − 0.55, 0.26 | 0.46 | 0.05 | ||
Control | 2.4 [1.3] | 2.4 [1.4] | ||||
Exergames | 2.3 [1.1] | 2.2 [1.2] | ||||
5-item GDS (0–5) [SD] | 0.21 | − 0.24, 0.65 | 0.34 | 0.04 | ||
Control | 1.4 [1.3] | 0.98 [1.1] | ||||
Exergames | 1.2 [1.3] | 1.0 [1.3] | ||||
TUG (s) [SD] | − 0.82 | − 3.62 to 1.98 | 0.54 | < 0.001 | ||
Control | 20.4 [14.3] | 20.7 [13.3] | ||||
Exergames | 17.5 [9.0] | 17.8 [10.4] | ||||
EQ5D5L-VAS (0–100) [SD] | 3.86 | − 6.46 to 14.17 | 0.44 | 0.05 | ||
Control | 71.2 [18.3] | 67.2 [22.7] | ||||
Exergames | 71.2 [21.4] | 70.6 [21.1] | ||||
PASE score (0–400) [SD] | − 0.97 | − 19.54 to 17.60 | 0.91 | 0.10 | ||
Control | 66.8 [38.2] | 72.3 [41.5] | ||||
Exergames | 75.1 [50.5] | 77.5 [43.1] |
Unless otherwise stated, means (SD) are reported
BBS Berg Balance Scale, SD standard deviation, ACE III Addenbrooke’s Cognitive Examination–III, 7-Item FES-I 7-Item Falls Efficacy Scale-International, VAS visual analogue scale, FRAT Falls Risk Assessment Tool, GDS Geriatric Depression Scale, TUG Timed Up and Go, EQ5D5L-VAS European Quality of Life 5 Dimensions -Visual Analogue Scale, PASE Physical Activity Scale for the Elderly
*Outcome (e.g. BBS) at 12 weeks adjusted for baseline value of outcome measure, region (Manchester/Glasgow) and site (random effect)